Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| LGD-4033 (Ligandrol) | SR-9009 (Stenabolic) | |
|---|---|---|
| Category | SARMs | SARMs |
| Standard Dose | Research indicates 5-10 mg daily orally for 8-12 weeks. Phase 1 data showed significant lean mass gains at 1 mg/day. | Research indicates 20-30 mg daily orally, split into 3-4 doses due to very short half-life (~4 hours). Some users prefer sublingual administration for improved bioavailability. |
| Timing | Once daily, consistent timing. Half-life approximately 24-36 hours. No food timing requirements. | Split into 3-4 doses throughout the day due to ~4-hour half-life. Example: 7am, 11am, 3pm, 7pm. Avoid late-night dosing as REV-ERB modulation may affect circadian rhythm and sleep. |
| Cycle Duration | 8-12 week cycles maximum. PCT strongly recommended after all but the shortest/lowest-dose cycles. | 8-12 week cycles. No HPG suppression. Cycling recommended due to limited long-term data. |
| Evidence Level | moderate_human | animal_plus_anecdotal |
LGD-4033 is a potent nonsteroidal selective androgen receptor modulator with high AR binding affinity (Ki of approximately 1 nM). It demonstrates strong anabolic activity in muscle and bone with significantly reduced androgenic activity in prostate tissue, achieving an anabolic-to-androgenic ratio of approximately 10:1. LGD-4033 activates the AR with full agonist efficacy in muscle, upregulating the PI3K/Akt/mTOR pathway for protein synthesis and satellite cell recruitment. It produces dose-dependent suppression of SHBG, total testosterone, LH, and FSH, indicating significant HPG axis suppression even at low doses.
Research indicates 5-10 mg daily orally for 8-12 weeks. Phase 1 data showed significant lean mass gains at 1 mg/day.
Once daily, consistent timing. Half-life approximately 24-36 hours. No food timing requirements.
8-12 week cycles maximum. PCT strongly recommended after all but the shortest/lowest-dose cycles.
SR-9009 is a synthetic agonist of REV-ERBa and REV-ERBb, nuclear receptors that form the repressive limb of the circadian clock and regulate metabolic gene expression. REV-ERB activation represses BMAL1/CLOCK transcription, modulating circadian rhythm. In skeletal muscle, SR-9009 increases mitochondrial count and oxidative capacity by upregulating mitochondrial biogenesis genes. It enhances fatty acid and glucose oxidation, increases exercise endurance, and reduces lipogenesis in the liver. SR-9009 also reduces inflammatory gene expression via NF-kB pathway suppression. Recent research has identified significant REV-ERB-independent effects, suggesting the mechanism is more complex than initially characterized.
Research indicates 20-30 mg daily orally, split into 3-4 doses due to very short half-life (~4 hours). Some users prefer sublingual administration for improved bioavailability.
Split into 3-4 doses throughout the day due to ~4-hour half-life. Example: 7am, 11am, 3pm, 7pm. Avoid late-night dosing as REV-ERB modulation may affect circadian rhythm and sleep.
8-12 week cycles. No HPG suppression. Cycling recommended due to limited long-term data.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →